Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Descriptor ID |
D019008
|
MeSH Number(s) |
G07.690.773.984.395
|
Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 2 | 6 | 8 |
1996 | 3 | 15 | 18 |
1997 | 3 | 10 | 13 |
1998 | 6 | 16 | 22 |
1999 | 7 | 12 | 19 |
2000 | 4 | 14 | 18 |
2001 | 4 | 17 | 21 |
2002 | 14 | 14 | 28 |
2003 | 14 | 39 | 53 |
2004 | 19 | 29 | 48 |
2005 | 25 | 44 | 69 |
2006 | 26 | 53 | 79 |
2007 | 45 | 58 | 103 |
2008 | 41 | 52 | 93 |
2009 | 51 | 59 | 110 |
2010 | 47 | 76 | 123 |
2011 | 57 | 84 | 141 |
2012 | 62 | 71 | 133 |
2013 | 54 | 60 | 114 |
2014 | 56 | 65 | 121 |
2015 | 69 | 83 | 152 |
2016 | 71 | 77 | 148 |
2017 | 59 | 72 | 131 |
2018 | 50 | 82 | 132 |
2019 | 48 | 82 | 130 |
2020 | 51 | 76 | 127 |
2021 | 47 | 37 | 84 |
2022 | 4 | 25 | 29 |
2023 | 7 | 24 | 31 |
2024 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer. BMC Cancer. 2024 Feb 19; 24(1):233.
-
Degradation trumps mutations in cancer. Science. 2024 Feb 02; 383(6682):480-481.
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Mar; 38(3):475-481.
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024 01 23; 8(2):388-398.
-
Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer. Cancer Res. 2024 01 16; 84(2):291-304.
-
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024 Feb; 30(2):498-506.
-
Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development. Eur J Pharmacol. 2024 Feb 05; 964:176304.
-
Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2023 12 15; 29(24):5183-5195.
-
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543.
-
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Rep Med. 2023 12 19; 4(12):101312.